Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2021-02-12 1:30 pm Purchase | 13G | INOZYME PHARMA INC INZY | New Enterprise Associates 15 L.P. | 2,437,689 10.4% | 2,437,689 (New Position) | View |
| 2021-02-09 5:08 pm Unchanged | 13G | INOZYME PHARMA INC INZY | Pivotal bioVenture Partners Fund I L.P. | 1,591,154 6.8% | 0 (Unchanged) | View |
| 2021-02-01 4:31 pm Sale | 13D | INOZYME PHARMA INC INZY | Novo Holdings A/S | 2,194,379 9.4% | -375,000 (-14.59%) | View |
| 2020-10-05 4:45 pm Unchanged | 13D | INOZYME PHARMA INC INZY | Novo Holdings A/S | 2,569,379 11% | 0 (Unchanged) | View |
| 2020-08-07 5:21 pm Purchase | 13D | INOZYME PHARMA INC INZY | Longitude Capital Partners III LLC | 2,819,379 12.1% | 2,819,379 (New Position) | View |
| 2020-08-06 10:58 am Purchase | 13G | INOZYME PHARMA INC INZY | Flynn James E | 1,150,299 5.15% | 1,150,299 (New Position) | View |
| 2020-08-04 08:30 am Purchase | 13D | INOZYME PHARMA INC INZY | Pivotal bioVenture Partners Fund I L.P. | 1,591,154 7.1% | 1,591,154 (New Position) | View |
| 2020-07-29 4:42 pm Purchase | 13D | INOZYME PHARMA INC INZY | Novo Holdings A/S | 2,569,379 11.5% | 2,569,379 (New Position) | View |